Ixazomib Citrate is a prodrug of ixazomib, a protease inhibitor used as a second-line treatment of multiple myleoma. When in its biologically active form, ixazomib can inhibit angiogensis and induce apoptosis by activating apoptotic pathways and upregulating tumor-suppressor genes.
|Mechanism of Action||Ixazomib is able to inhibit the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, and at higher concentrations inhibit the caspase-like (β1) and trypsin-like (β2) proteolytic sites.|
|References||Offidani, M., Corvatta, L., Caraffa, P., Gentili, S., Maracci, L., & Leoni, P. (2014). An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. OncoTargets and Therapy, 1793. doi:10.2147/ott.s49187|